Is Genenta Science Stock a Good Investment?
Genenta Science Investment Advice | GNTA |
- Examine Genenta Science's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Genenta Science's leadership team and their track record. Good management can help Genenta Science navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Genenta Science's business and its evolving consumer preferences.
- Compare Genenta Science's performance and market position to its competitors. Analyze how Genenta Science is positioned in terms of product offerings, innovation, and market share.
- Check if Genenta Science pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Genenta Science's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Genenta Science SpA stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Genenta Science SpA is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Genenta Science Stock
Researching Genenta Science's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 39.0% of the company shares are held by company insiders. The book value of Genenta Science was currently reported as 0.68. The company recorded a loss per share of 0.57. Genenta Science SpA had not issued any dividends in recent years.
To determine if Genenta Science is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Genenta Science's research are outlined below:
| Genenta Science SpA had very high historical volatility over the last 90 days | |
| Net Loss for the year was (8.91 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Genenta Science SpA currently holds about 37.24 M in cash with (6.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.04. | |
| Roughly 39.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: What drives Genenta Science S.p.A. Depositary Receipt stock price - Explosive trading opportunities - jammulinksnews.com |
Genenta Science uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Genenta Science SpA. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Genenta Science's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 24th of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 24th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Genenta Science's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Genenta Science is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Genenta Science SpA backward and forwards among themselves. Genenta Science's institutional investor refers to the entity that pools money to purchase Genenta Science's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Allianz Se | 2025-03-31 | 233.6 K | Alti Global Inc | 2025-03-31 | 200.3 K | Algebris Investment Management (uk) Llp | 2025-03-31 | 100 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 3.4 K | Ubs Group Ag | 2025-03-31 | 91.0 | Citadel Advisors Llc | 2025-03-31 | 0.0 |
Genenta Science's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 68.04 M.Market Cap |
|
Genenta Science's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.60) | (0.57) | |
| Return On Capital Employed | (0.65) | (0.69) | |
| Return On Assets | (0.60) | (0.57) | |
| Return On Equity | (0.66) | (0.62) |
Determining Genenta Science's profitability involves analyzing its financial statements and using various financial metrics to determine if Genenta Science is a good buy. For example, gross profit margin measures Genenta Science's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Genenta Science's profitability and make more informed investment decisions.
Please note, the presentation of Genenta Science's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Genenta Science's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Genenta Science's management manipulating its earnings.
Evaluate Genenta Science's management efficiency
Genenta Science SpA has return on total asset (ROA) of (0.3284) % which means that it has lost $0.3284 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5413) %, meaning that it created substantial loss on money invested by shareholders. Genenta Science's management efficiency ratios could be used to measure how well Genenta Science manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.57. In addition to that, Return On Capital Employed is expected to decline to -0.69. At present, Genenta Science's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 19.1 M, whereas Net Tangible Assets are forecasted to decline to about 13.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.01 | 1.10 | |
| Tangible Asset Value | 28 M | 24.9 M | |
| Tangible Book Value Per Share | 1.01 | 1.10 | |
| Enterprise Value Over EBITDA | (6.00) | (6.30) | |
| Price Book Value Ratio | 4.59 | 6.97 | |
| Enterprise Value Multiple | (6.00) | (6.30) | |
| Price Fair Value | 4.59 | 6.97 | |
| Enterprise Value | 89.6 M | 128.7 M |
Understanding the operational decisions made by Genenta Science management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 0.582 |
Basic technical analysis of Genenta Stock
As of the 23rd of July, Genenta Science retains the Downside Deviation of 3.78, market risk adjusted performance of (0.12), and Risk Adjusted Performance of 0.013. Genenta Science technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Genenta Science's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Genenta Science insiders, such as employees or executives, is commonly permitted as long as it does not rely on Genenta Science's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Genenta Science insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Rosenwald Lindsay A Md over six months ago Disposition of 506245 shares by Rosenwald Lindsay A Md of Genenta Science subject to Rule 16b-3 | ||
Driscoll Martin J over six months ago Acquisition by Driscoll Martin J of 4999 shares of Genenta Science at 0.25 subject to Rule 16b-3 | ||
Rosenwald Lindsay A Md over a year ago Disposition of 64562 shares by Rosenwald Lindsay A Md of Genenta Science subject to Rule 16b-3 | ||
Rosenwald Lindsay A Md over a year ago Disposition of 2287 shares by Rosenwald Lindsay A Md of Genenta Science subject to Rule 16b-3 |
Genenta Science's Outstanding Corporate Bonds
Genenta Science issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Genenta Science SpA uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Genenta bonds can be classified according to their maturity, which is the date when Genenta Science SpA has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand Genenta Science's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Genenta Science's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.013 | |||
| Market Risk Adjusted Performance | (0.12) | |||
| Mean Deviation | 2.64 | |||
| Semi Deviation | 3.33 | |||
| Downside Deviation | 3.78 | |||
| Coefficient Of Variation | 17994.61 | |||
| Standard Deviation | 4.37 | |||
| Variance | 19.11 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | 0.0327 | |||
| Total Risk Alpha | (0.80) | |||
| Sortino Ratio | (0.04) | |||
| Treynor Ratio | (0.13) | |||
| Maximum Drawdown | 29.79 | |||
| Value At Risk | (6.29) | |||
| Potential Upside | 4.74 | |||
| Downside Variance | 14.32 | |||
| Semi Variance | 11.11 | |||
| Expected Short fall | (3.03) | |||
| Skewness | 2.75 | |||
| Kurtosis | 16.49 |
| Risk Adjusted Performance | 0.013 | |||
| Market Risk Adjusted Performance | (0.12) | |||
| Mean Deviation | 2.64 | |||
| Semi Deviation | 3.33 | |||
| Downside Deviation | 3.78 | |||
| Coefficient Of Variation | 17994.61 | |||
| Standard Deviation | 4.37 | |||
| Variance | 19.11 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | 0.0327 | |||
| Total Risk Alpha | (0.80) | |||
| Sortino Ratio | (0.04) | |||
| Treynor Ratio | (0.13) | |||
| Maximum Drawdown | 29.79 | |||
| Value At Risk | (6.29) | |||
| Potential Upside | 4.74 | |||
| Downside Variance | 14.32 | |||
| Semi Variance | 11.11 | |||
| Expected Short fall | (3.03) | |||
| Skewness | 2.75 | |||
| Kurtosis | 16.49 |
Consider Genenta Science's intraday indicators
Genenta Science intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Genenta Science stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Genenta Science time-series forecasting models is one of many Genenta Science's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Genenta Science's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Genenta Stock media impact
There is far too much social signal, news, headlines, and media speculation about Genenta Science that are available to investors today. This information is accessible both publicly - through Genenta Science's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Genenta-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Genenta Science news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Genenta Science relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Genenta Science's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Genenta Science alpha.
Genenta Science Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Genenta Science can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Genenta Science Corporate Management
| Carlo MD | Chief Development | Profile | |
| Richard Slansky | Chief Officer | Profile | |
| Tim Obara | Head Devel | Profile | |
| Luigi MD | CoFounder Board | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genenta Science SpA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genenta Science. If investors know Genenta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genenta Science listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Genenta Science SpA is measured differently than its book value, which is the value of Genenta that is recorded on the company's balance sheet. Investors also form their own opinion of Genenta Science's value that differs from its market value or its book value, called intrinsic value, which is Genenta Science's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genenta Science's market value can be influenced by many factors that don't directly affect Genenta Science's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Genenta Science's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Genenta Science is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genenta Science's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.